{"product_id":"ucb-bcg-matrix","title":"UCB Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe BCG Matrix is your essential guide to understanding a company's product portfolio, categorizing them into Stars, Cash Cows, Dogs, and Question Marks. This framework helps identify growth opportunities and resource allocation strategies. \u003c\/p\u003e\n\u003cp\u003eReady to move beyond the basics and unlock actionable insights? Purchase the full BCG Matrix to receive a detailed breakdown of each product's position, complete with data-driven recommendations for optimizing your business strategy and driving future success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBimzelx (bimekizumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBimzelx is a significant growth engine for UCB, demonstrating robust performance across several key therapeutic areas including psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.\u003c\/p\u003e\n\u003cp\u003eThe drug is on track to achieve blockbuster status, with sales projected to reach €1.3 billion by 2025, potentially representing a substantial share of UCB's overall revenue by 2033.\u003c\/p\u003e\n\u003cp\u003eBroad regulatory approvals and ongoing market introductions in major regions such as the U.S., Europe, and China underscore Bimzelx's strong market penetration and substantial growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRystiggo (rozanolixizumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRystiggo (rozanolixizumab) is a key driver of UCB's growth, demonstrating robust initial sales in its first year.  By the close of 2024, it had already reached more than 1,200 patients across the U.S., Japan, and Europe, signaling strong market adoption for this generalized myasthenia gravis treatment. \u003c\/p\u003e\n\u003cp\u003eThe recent approval for at-home self-administration in Japan is a significant development, expected to further boost Rystiggo's accessibility and revenue contribution. This strategic move positions Rystiggo as a high-potential product within UCB's portfolio, likely categorizing it as a Star in the BCG matrix due to its strong market performance and growth prospects. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZilbrysq (zilucoplan)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZilbrysq (zilucoplan) is positioned as a potential Star in UCB's BCG Matrix, reflecting its status as a new product with high growth potential in the generalized myasthenia gravis (gMG) market. Its unique profile as the first and only once-daily subcutaneous C5 complement inhibitor for gMG provides a significant competitive edge.\u003c\/p\u003e\n\u003cp\u003eThe product has demonstrated a strong launch, exceeding analyst sales expectations, which underscores its promising market penetration and revenue generation capabilities. For example, UCB reported that Zilbrysq achieved €25 million in sales in the first quarter of 2024, surpassing initial market forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFintepla (fenfluramine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFintepla, UCB's treatment for rare epileptic syndromes such as Dravet Syndrome and Lennox-Gastaut Syndrome, has demonstrated robust performance with double-digit growth and significant patient reach worldwide.\u003c\/p\u003e\n\u003cp\u003eUCB projects Fintepla will maintain its market presence in the U.S. through Q4 2033, underscoring its role as a key growth contributor in a critical medical area. The drug's recent approval in Japan for Lennox-Gastaut syndrome further broadens its global accessibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Presence:\u003c\/strong\u003e U.S. market presence anticipated until Q4 2033.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Trajectory:\u003c\/strong\u003e Demonstrated double-digit growth globally.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeographic Expansion:\u003c\/strong\u003e Recently approved in Japan for Lennox-Gastaut syndrome.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTherapeutic Area:\u003c\/strong\u003e Addresses rare epileptic syndromes like Dravet and Lennox-Gastaut.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvenity (romosozumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvenity (romosozumab) represents a significant asset for UCB, firmly positioned as a star in the BCG matrix due to its strong market leadership in the bone builder segment. This drug has demonstrated robust sales growth, especially noted in European markets, contributing substantially to UCB's overall financial performance. For instance, UCB reported Evenity net sales of €516 million in 2023, a notable increase from previous years, highlighting its growing market penetration and revenue generation capabilities. \u003c\/p\u003e\n\u003cp\u003eThe drug's success is further amplified by strategic global distribution partnerships with Amgen and Astellas. These collaborations are instrumental in maximizing Evenity's market share and unlocking its considerable growth potential. The drug's ability to treat severe osteoporosis in postmenopausal women, a significant patient population, ensures sustained demand. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Leadership:\u003c\/strong\u003e Evenity is a leading treatment for severe osteoporosis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Growth:\u003c\/strong\u003e The drug experienced significant sales increases, particularly in Europe, reaching €516 million globally in 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Reach:\u003c\/strong\u003e Partnerships with Amgen and Astellas facilitate worldwide distribution.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Impact:\u003c\/strong\u003e Evenity's net earnings are a substantial contributor to UCB's operating income.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUCB's Top Performers: Stars of Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThese products are characterized by high market share and high growth potential, indicating they are key drivers of UCB's current and future success.\u003c\/p\u003e\n\u003cp\u003eTheir strong performance and broad market adoption position them as significant contributors to the company's revenue and profitability.\u003c\/p\u003e\n\u003cp\u003eUCB's strategic focus on these \"Stars\" is crucial for maintaining its competitive edge and achieving sustained growth in the pharmaceutical sector.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003e2023 Sales (approx.)\u003c\/th\u003e\n\u003cth\u003eGrowth Potential\u003c\/th\u003e\n\u003cth\u003eBCG Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBimzelx\u003c\/td\u003e\n\u003ctd\u003ePsoriasis, PsA, AS, HS\u003c\/td\u003e\n\u003ctd\u003e€600 million\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRystiggo\u003c\/td\u003e\n\u003ctd\u003eGeneralized Myasthenia Gravis\u003c\/td\u003e\n\u003ctd\u003e€100 million (initial)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZilbrysq\u003c\/td\u003e\n\u003ctd\u003eGeneralized Myasthenia Gravis\u003c\/td\u003e\n\u003ctd\u003e€25 million (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFintepla\u003c\/td\u003e\n\u003ctd\u003eRare Epileptic Syndromes\u003c\/td\u003e\n\u003ctd\u003e€300 million (est.)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvenity\u003c\/td\u003e\n\u003ctd\u003eSevere Osteoporosis\u003c\/td\u003e\n\u003ctd\u003e€516 million\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis BCG Matrix overview provides a strategic breakdown of UCB's product portfolio, categorizing each into Stars, Cash Cows, Question Marks, and Dogs to guide investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eInstantly visualize your portfolio's health, alleviating the pain of strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCimzia (certolizumab pegol)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCimzia, UCB's immunology drug, has historically been a significant revenue generator, fitting the profile of a cash cow. Despite facing anticipated pricing pressures and the expiration of its U.S. and EU patents in 2024, its established market position continues to yield consistent cash flow for UCB.\u003c\/p\u003e\n\u003cp\u003eThe potential for delayed biosimilar competition and UCB's planned regain of rights in Japan by 2026 are factors that could further bolster Cimzia's cash-generating capabilities in the coming years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBriviact (brivaracetam)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBriviact, UCB's epilepsy treatment, is a strong performer, consistently achieving double-digit sales growth globally. This robust expansion has allowed it to surpass its peak sales projections, originally set for 2026, well ahead of schedule. \u003c\/p\u003e\n\u003cp\u003eThis early success highlights Briviact's significant market penetration and its capacity to generate substantial, reliable cash flow for UCB. Its established position within the epilepsy treatment landscape solidifies its role as a dependable cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeppra (levetiracetam)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKeppra (levetiracetam), a cornerstone epilepsy treatment for UCB, has significantly impacted millions of patients.  Even after its patent expiry over a decade ago and facing substantial generic competition, it continues to be a notable revenue generator for the company.\u003c\/p\u003e\n\u003cp\u003eWhile generic versions have eroded its market share, Keppra's established patient base and continued prescription volume likely ensure a stable, though diminishing, stream of cash flow for UCB. This sustained contribution solidifies its position as a mature product within the company's portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVimpat (lacosamide)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVimpat (lacosamide) has been a cornerstone in UCB's central nervous system (CNS) franchise, consistently driving significant revenue.  Despite its patent expiration in 2022, the drug's established efficacy in treating epilepsy means it continues to be a recognized treatment option.\u003c\/p\u003e\n\u003cp\u003eWhile Vimpat's peak sales were substantial, the advent of generic alternatives naturally impacts its cash-generating capabilities.  For 2024, UCB's reported sales for Vimpat were €1.3 billion, a decrease from previous years reflecting ongoing market dynamics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eVimpat's historical contribution to UCB's CNS portfolio remains notable.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePatent expiration in 2022 has led to increased generic competition.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReported sales for Vimpat in 2024 reached €1.3 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe drug's ongoing use in epilepsy continues to provide some revenue stream.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brands in Europe \u0026amp; International Countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUCB's established brands in Europe and other international markets represent key Cash Cows. Despite some strategic divestments, such as neurology and allergy assets in China during late 2024, these mature products remain significant contributors to the company's net sales, demonstrating resilience and sustained market presence.\u003c\/p\u003e\n\u003cp\u003eThese brands, characterized by strong market share and established customer loyalty, generate consistent and predictable cash flow. While their growth potential might be more modest compared to newer products, their stability is crucial for funding UCB's innovation pipeline and other strategic initiatives.\u003c\/p\u003e\n\u003cp\u003eThe financial performance of these established brands underscores their Cash Cow status:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsistent Revenue Generation:\u003c\/strong\u003e These brands continue to deliver reliable revenue streams, supporting overall financial health.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMature Market Position:\u003c\/strong\u003e Their long-standing presence in key European and international markets ensures a solid customer base.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCash Flow Contribution:\u003c\/strong\u003e The predictable cash flow generated by these products is vital for reinvestment and operational stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-Divestment Performance:\u003c\/strong\u003e Even after the late 2024 divestments in China, these established brands in other regions maintain their strong sales contributions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUCB's Cash Cows: Steady Revenue Amidst Market Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows are mature products with strong market positions that generate consistent, predictable cash flow, essential for funding new ventures. UCB's portfolio includes several such products, demonstrating their enduring value even as they face market evolution.\u003c\/p\u003e\n\u003cp\u003eThese established brands, despite patent expirations and generic competition, continue to be significant revenue contributors. Their resilience highlights UCB's ability to maintain market share and customer loyalty for its key therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eThe consistent cash flow from these products is vital for UCB's overall financial stability and its capacity to invest in research and development for future growth drivers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003e2024 Sales (Approx.)\u003c\/th\u003e\n\u003cth\u003eKey Characteristic\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCimzia\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003e€1.2 billion+\u003c\/td\u003e\n\u003ctd\u003eEstablished market, patent expiry 2024 (US\/EU)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBriviact\u003c\/td\u003e\n\u003ctd\u003eEpilepsy\u003c\/td\u003e\n\u003ctd\u003e€0.8 billion+\u003c\/td\u003e\n\u003ctd\u003eStrong double-digit growth, surpassed peak sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeppra\u003c\/td\u003e\n\u003ctd\u003eEpilepsy\u003c\/td\u003e\n\u003ctd\u003e€0.5 billion+\u003c\/td\u003e\n\u003ctd\u003eMature, significant generic competition, stable revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVimpat\u003c\/td\u003e\n\u003ctd\u003eEpilepsy\u003c\/td\u003e\n\u003ctd\u003e€1.3 billion\u003c\/td\u003e\n\u003ctd\u003ePatent expired 2022, generic competition, still significant revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eUCB BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe BCG Matrix document you are currently previewing is the exact, fully formatted report you will receive upon purchase. This comprehensive analysis tool, designed to guide strategic business decisions, is ready for immediate download and application. You can confidently expect the same high-quality content and professional design in the final version, enabling you to effectively categorize and strategize your business units or product portfolio. No watermarks or demo content will be present; it's the complete strategic resource you need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610903134585,"sku":"ucb-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ucb-bcg-matrix.png?v=1754748378","url":"https:\/\/growthsharematrix.com\/products\/ucb-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}